Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024

As 2024 comes to a close, we reflect on the invaluable insights shared in Dermatology Times' Interview Intersection column. Throughout the year, we engaged with leading dermatologists and skin care experts, uncovering the latest advancements, clinical perspectives, and personal stories shaping the field. From emerging treatment options to tackling complex skin conditions, these interviews have provided a wealth of knowledge to inform and inspire. Here’s a look back at some of the most memorable moments and key takeaways from this year’s conversations.

Maral Kibarian Skelsey, MD, Shares Insights Into DermTech’s 2-GEP Assay Success

DermTech’s study results demonstrated that in patients with Fitzpatrick skin types IV-VI, all 3 melanomas diagnosed by histopathology were correctly identified by the 2-GEP assay as positive for LINC00518 and PRAME.

Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque Psoriasis

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about published data supporting JNJ-2113's potential in this indication.

John Barbieri, MD, MBA, FAAD: Evidence-Based Recommendations and Good Practice Statements From the AAD Acne Guidelines

Barbieri spoke with Dermatology Times to discuss the new guidelines and the recommendations and good practice statements included.

Valisure's David Light Unpacks Benzene Findings, Stability Testing, and Discourse

Following the announcement of Valisure's findings related to benzene and benzoyl peroxide acne products, Dermatology Times spoke with David Light, co-founder and president of the laboratory behind the report, to discuss the findings, the role of stability testing requirements, and quelling fear-filled online discourse.

Navigating the Path to Equity: Insights from Aletha Maybank, MD, MPH

"We cannot do health equity outside of an institution unless we figure out how to get our own house in order," the AMA leader said.

How is Artificial Intelligence Growing Up?

Joseph Zabinski, PhD, MEM, of OM1, shared insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.

Muneeb Shah, DO: Behind the Scenes of Launching a Skin Care Brand

Shah discussed the science behind his products, as well as the challenges he didn’t anticipate when launching Remedy.

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.

Striving for Melanoma Advancements With the Melanoma Research Alliance

Marc Hurlbert, PhD, discussed how the Melanoma Research Alliance works with dermatology clinicians to provide fundings and resources for melanoma research.

More Clinicians are Needed in the Fight Against Skin Cancer

Andrew Baker, MBA, MPAS, PA-C, discussed his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.

Boxed Warnings: What Should Dermatology Clinicians Know?

Jason Hawkes, MD, MS, broke down boxed warning pros and cons and research addressing several boxed warnings.

Comparing AD Guidelines From Around the World

Robert Sidbury, MD, MPH, addressed the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Turn Therapeutics' Atopic Dermatitis Candidate Achieves 57% Reduction in Disease Severity in 7 Days

Bradley Burnam discussed results from an in-vivo model of atopic dermatitis.

Exploring the Intersection of Permanent Makeup and Dermatology

Walter Liszewski, MD, shared insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

Nanette Silverberg, MD: Taking an Aggressive Treatment Approach to Progressive Vitiligo

Silverberg discussed her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Chesahna Kindred, MD, MBA, FAAD: Expert Insights on Enhancing Dermatological Care for Patients with Skin of Color

Kindred spoke with Dermatology Times to discuss AbbVie's Science of Skin event and improving access to equitable dermatological care.

“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

John Browning, MD, FAAD, FAAP, MBA, discussed the new online platform that allows young patients to share their skin journey with others.

Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

Scientific Advancements in Atopic Dermatitis with Matthew Zirwas, MD

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

Q&A: Amy McMichael, MD, Discusses 48-Week VISIBLE Study Results on Psoriasis in Patients With Skin of Color

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Benzene in Benzoyl Peroxide at Room Temperature: What Comes Next?

Christopher Bunick, MD, PhD, reviewed the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.

Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis

Shawn Kwatra, MD, reviewed key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Updates on the Latest Cosmetic Treatments in Medical Care

Affordable at-home treatments, including microneedling and benzoyl peroxide, were top pearls at Chilukuri's Elevate-Derm session.

From Clinic to Industry: Insights Into the MSL Role and PA Advocacy

At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.

Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

Jason Hawkes, MD, MS: Looking Back on 2024, Ahead to 2025

Hawkes shared his excitement for the near future of dermatology, recognizing the increasing ability to provide tailored care to patients.

The Importance and Role of Advocacy in the Approval of ICD-10 Codes for CCCA and FFA

Itisha S. Jefferson, a patient advocate and medical student, discussed the significance of new ICD-10 codes for CCCA and FFA, improving diagnosis and care.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.